

Disclosure of the total number of voting rights and shares as of April 30, 2024

Paris, France, May 27, 2024 – 6:00 pm CEST - ACTICOR BIOTECH (FR00140050J5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today discloses the total number of voting rights and shares as of April 30, 2024 (pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority).

- Listing Place: Euronext Growth Paris
- ISIN Code : FR00140050J5
- Web site: acticor-biotech.com

Date	Number of shares making up the share capital	Theoretical number of voting rights ⁽¹⁾	Number of voting rights excluding shares stripped of voting rights ⁽²⁾
April 30, 2024	15.755.227	15.755.227	15.510.598

- (1) In accordance with Article 223-111 of the AMF's General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.
- (2) The actual voting rights correspond to the total number of voting rights that can be exercised in a general meeting. They are calculated on the basis of the total number of voting rights attached to the total number of shares minus the shares without voting rights.

About ACTICOR BIOTECH

Acticor Biotech is a clinical-stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, particularly ischemic stroke.

The positive results of the phase 1b/2a study, ACTIMIS, published in January 2024 in the Lancet Neurology ([link to publication](#)) confirmed the safety profile of glenzocimab and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group of stroke patients. A post-hoc analysis of brain imaging at 0 and 24 hours using artificial intelligence confirmed these results, showing a reduction in the number and volume of intracerebral lesions in patients treated with glenzocimab.

On April 25, 2024, the company announced the initial results of the international phase 2/3 ACTISAVE study in the treatment of acute ischemic stroke, which showed no efficacy of glenzocimab on the primary endpoint, the proportion of patients with severe disability or death (mRS 4-6) 90 days after stroke, nor on the secondary endpoint, the proportion of patients returning to life without disability (mRS 0-2).

On May 15, 2024, Prof. Mikael Köhrmann (Principal Investigator of ACTISAVE) presented the main results of the study at the opening session of the European Stroke Organization Conference (ESOC), confirming the neutrality of the study on the primary and secondary endpoints, and showing trends in return to normal life (mRS 0-1), notably in sub-populations of patients with complete recanalization after mechanical thrombectomy.

Glenzocimab is being evaluated in 2 other clinical trials initiated by academic teams:

- GREEN: a phase 2/3 study in the treatment of stroke in thrombectomized patients, with a futility analysis after inclusion of the first 78 patients (30% of patients) expected in Q4 2024;
- LIBERATE: a Phase 2b LIBERATE trial in the treatment of myocardial infarction, with final results expected in Q4 2025.

Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa Foundation) and has been listed on Euronext Growth Paris since November 2021 (ISIN: FR00140050J5 - ALACT).

Contacts

ACTICOR BIOTECH

Gilles AVENARD, MD

CEO and Founder

gilles.avenard@acticor-biotech.com

Sophie BINAY, PhD

General Manager and CSO

Sophie.binay@acticor-biotech.com

NewCap

Mathilde BOHIN

Investor Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 94 95

NewCap

Arthur ROUILLÉ

Media Relations

acticor@newcap.eu

T. : +33 (0)1 44 71 00 15